Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

DISEASE CHARACTERISTICS: Histologically confirmed malignancy, including, but not limited to, any of the following: Renal cell carcinoma Melanoma Kaposi's sarcoma Breast, prostate, colorectal, or lung adenocarcinoma Bone and soft tissue sarcomas Lymphoma Myeloma Tumors of neuroendocrine and endothelial cell origin Stage IV disease Refractory disease, resistant to established treatments, or no effective treatment available Measurable or evaluable disease CNS metastases allowed if no prior definitive therapy within the past 3 months and no glucocorticoids required PATIENT CHARACTERISTICS: ECOG performance status 0-1 Granulocyte count > 1,500/mm^3 Platelet count > 100,000/mm^3 Creatinine < 1.0 times upper limit of normal (ULN) Creatinine clearance ≥ 60 mL/min Bilirubin < 1.5 times ULN AST/ALT < 1.5 times ULN Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after completion of study treatment No history of any of the following: Atrial fibrillation, atrial flutter, or other serious arrhythmia (excluding asymptomatic atrial and ventricular premature complexes) Congestive heart failure currently requiring treatment Angina pectoris Other severe cardiovascular disease (i.e., New York Heart Association class III or IV heart disease) No baseline ECG abnormalities suggestive of cardiac conduction delay, i.e., 1° or greater atrio-ventricular block and/or complete or incomplete (QRS > 120 ms) bundle branch block, or repolarization abnormalities (i.e., QTc ≥ 0.48 sec) No systemic infections requiring antibiotics within the past 14 days No known hepatitis B surface antigen positivity Psychologically prepared to participate in study treatment PRIOR CONCURRENT THERAPY: See Disease Characteristics At least 4 weeks since prior interferon (IFN) therapy and/or ≤ 400 million units of IFN At least 3 weeks since prior major surgery At least 3 weeks since prior radiation therapy or chemotherapy No prior solid organ allografts or allogeneic bone marrow transplantation No concurrent daily glucocorticoids except for physiological replacement No other concurrent medications known to prolong QT interval